Pancreatic enzyme therapy in cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 2, Issue 6, 2008, Pages 681-683

  Dodge, John A ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KREON; NUTRIZYME; PANCREAS ENZYME; PANCRELIPASE; UNCLASSIFIED DRUG;

COLON DISEASE; CYSTIC FIBROSIS; DIETARY INTAKE; DISEASE SEVERITY; DOSE CALCULATION; DRUG FORMULATION; DRUG SAFETY; DRUG STABILITY; EDITORIAL; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME REPLACEMENT; HUMAN; LIPID ABSORPTION; LUNG INFECTION; NONHUMAN; PANCREAS FUNCTION; PANCREAS INSUFFICIENCY; PROGNOSIS; RISK ASSESSMENT;

EID: 65449173950     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.6.681     Document Type: Editorial

References (16)

1. Fanconi G, Uehlinger E, Knauer C. Das coeliakensyndrom bei angeborener zysticher pankreasfibromatose und bronchiektasien. Wien. Med. Wochenschr. 86, 753-756 (1936).
2. Andersen DH. Cystic fibrosis of the pancreas and its relationship to celiac disease: a clinical and pathological study. Am. J. Dis. Child. 56, 344-399 (1938).
3. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the United Kingdom: 1947-2003. Eur. Resp. J. 82 (1), 394-399 (2007).
4. Heubi JE. Pancreatic enzyme-replacement therapy in CF: considerations for the USA. Expert Rev. Resp. Med. 2(5), 589-596 (2008).
5. O'Hare MMT, McMaster C, Dodge JA. Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use. J. Pediat. Gastroenterol. Nutr. 21(1), 59-63 (1995).
6. Lebenthal E. High strength pancreatic enzyme capsules associated with colonic strictures in patients with cystic fibrosis: 'more is not necessarily better'. J. Pediat. Gastroenterol. Nutr. 18, 423-425 (1994).
7. Reetsma K, di Sant'Agnese PA, Malm JR, Barker HG. Cystic fibrosis of the pancreas: Intestinal absorption of fat and fatty acid labelled with I131. Pediatrics 20, 525-532 (1958).
8. Kalivianakis M, Munch DM, Bijleveld CMA et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long chain fatty acids. Am. J. Clin. Nutr. 69, 127-134 (1999).
9. Strandvik B, Hansson L, Hernell O et al. Recombinant human bile salt-stimulated lipase improves lipid uptake and reduces the pancreatic enzyme supplementation in patients with cystic fibrosis. Pediat. Pulmonol. 38(Suppl. 27), 333 (2004).
10. Fitzsimmons SC, Burkhart GA, Borowitz D et al. High-dose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N. Eng. J. Med. 336, 1283-1289 (1997).
11. Serban DE, Florescu P, Miu N. Fibrosing colonopathy revealing cystic fibrosis in a neonate before any pancreatic enzyme supplementation. J. Pediat. Gastroenterol. Nutr. 35, 356-359 (2002).
12. Baxter P, Goldhill J, Hardcastle J et al. Enhanced intestinal glucose and alanine transport in cystic fibrosis. Gut 31, 817-820 (1990).
13. Cloutier M, Gingras D, Bendayan M. Internalisation and transcytosis of pancreatic enzymes by the intestinal mucosa. J. Histochem. Cytochem. 54, 781-794 (2006).
14. Smyth RL, Croft NM, O'Shea U et al. Intestinal inflammation in cystic fibrosis. Arch. Dis. Child. 82, 394-399 (2000).
15. Hyun E, Andrade-Gordon P, Steinhoff M, Vergnolle N. Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut 57, 1222-1229 (2008).
16. The Board of the European Cystic Fibrosis Society. Recommendations Regarding Presence of Phthalates in Some Enteric-coated Pancreatic Enzymes. Agreed document with US CFF and Canadian CFF. 5 September 2008.